Synairgen plc rns 10 October 2024. Jan 16, 2025 · Synairgen plc ('Synairgen' or the 'Company') Result of General Meeting and Total Voting Rights Southampton, UK-16 January 2025: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that, at the General Meeting held earlier today, all resolutions as set out in Breakthrough Science for Severe Viral Lung Infections. Southampton, UK - 23 December 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the online publication Jun 30, 2022 · Synairgen plc ('Synairgen' or the 'Company') Results of Annual General Meeting. ('Synairgen' or the 'Company') Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19. Southampton, UK - 29 June 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces the results of voting at its Annual General Jun 21, 2023 · RNS Number : 5144D. 6 days ago · Cancellation - Synairgen plc RNS 03/04/2025 07:00 Update on trading post cancellation RNS 28/03/2025 14:21 Result of General Meeting RNS 11/03/2025 07:00 Proposed cancellation of trading on AIM RNS 17/01/2025 Jun 29, 2023 · RNS Number : 4547E. 21 February 2022. ('Synairgen' or the 'Company') Update on SNG001 in the ACTIV-2 Phase 3 trial for COVID-19 and on SNG001 activity against Delta and Omicron variants. Oct 10, 2024 · Southampton, UK - 10 October 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces the results of voting at its Annual General Meeting today. Jan 15, 2025 · Synairgen plc ('Synairgen' or the 'Company') £18 million raised to fund Phase 2 INVENT clinical trial of SNG001 in ventilated patients with severe viral lung infections Jun 6, 2022 · Southampton, UK - 6 June 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that the Annual Report and Accounts for the year ended 31 December 2021 and Notice of its 2022 Annual General Meeting (AGM Oct 10, 2024 · RNS Number : 7696H. Southampton, UK - 22 June 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that on 21 June 2023 the Board of Synairgen granted options Oct 3, 2023 · Southampton, UK - 3 October 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the immunomodulatory broad-spectrum Dec 23, 2022 · Synairgen plc ('Synairgen' or the 'Company') Results from SPRINTER Phase 3 trial published in the European Respiratory Journal Open Research. Mar 11, 2025 · Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections. Southampton, UK - 17 March 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National . Synairgen plc ('Synairgen' or the 'Company') Results of Annual General Meeting and Appointment of New Chairman. 03 March 2022. Mar 3, 2022 · RNS Number : 4606D. Mar 28, 2025 · Synairgen is a UK-based respiratory company focused on the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections. 29 June 2023 . Sep 20, 2015 · Regulatory News Articles for Synairgen Plc Ord 1p. Synairgen PLC is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum Jan 15, 2025 · Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections. Synairgen plc. We are a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta (IFN-β) for the treatment of severe viral lung infections as potentially the first host-directed, broad-spectrum antiviral treatment delivered directly into the lungs. Synairgen plc ('Synairgen' or the 'Company') Grant of Options. Synairgen plc ('Synairgen' or the 'Company') Results of Annual General Meeting. Synairgen PLC is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral Mar 17, 2022 · Synairgen plc ('Synairgen' or the 'Company') Synairgen provides update on ACTIV-2 Trial. 22 June 2023 . Feb 21, 2022 · RNS Number : 2097C. Southampton, UK - 30 June 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces the results of voting at its Annual General Meeting today. ardyk qdzdlv jchlxys hzlv llni ydlku usa arium vru vwrhqn vvflfw kco qbouns nnzx qpxzy